| Name | Title | Contact Details |
|---|
CareKinesis is the first national PACE-centric, medication management and distribution pharmacy that focuses on reducing medication-related risk while enhancing economic, clinical, and humanistic outcomes.
To improve the health status of the communities we serve through compassionate, high quality, accessible and cost effective care. We value those who provide our care and those who receive our care. We accomplish this through partnership, dedication, service, quality and stewardship.
Explore the many facilities, parks and programs that the Skokie Park District has to offer.
Heart `n Home Hospice and Palliative Care is a local company established on the rural values of hard work and a foundation of integrity. Family owned and operated, Heart `n Home was established in March of 2004 and became Medicare Certified on June 17, 2004. Our core philosophy is to optimize the quality of life for individuals in the final stages of terminal illness. The Heart `n Home ethic and focus of "doing what`s right" has allowed us to flourish and grow to be one of the leading hospice providers in Idaho and Eastern Oregon. This is the epitome of what Heart `n Home is all about. We strive to do what is right for our patients and families; and treasure the privilege of walking people to the gates of eternity. Heart `n Home has over 160 employees and provides hospice and palliative care services to 11 counties in Idaho and Oregon. We have offices in Fruitland (Corporate Headquarters), Caldwell, Emmett, Meridian, Baker City, La Grande, La Pine, and Bend.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.